Cellectis Acquires Vectocell Technology to Accelerate Therapeutic Development Programs

15-Oct-2009 - Cellectis S.A. announced that it has acquired the Vectocell® intracellular delivery technology from Diatos SA in order to optimize the efficacy of its drug candidates. The Vectocell® technology platform can improve the performance of a therapeutic compound by enabling specific entry into the ...

Diatos Announces Acquisition of Specialty Cancer Product DaunoXome from Gilead Sciences

15-May-2006 - Diatos SA announced an exclusive licensing agreement with Gilead Sciences, Inc. on the worldwide development and commercialization rights to DaunoXome. DaunoXome is a marketed liposomal formulation of daunorubicin, which has been approved for AIDS/HIV-related Kaposi's sarcoma and is sold by ...

Diatos acquires full commercialization rights in Europe for DTS-201

31-Mar-2006 - Diatos SA, announced that Medarex has granted full European commercialization rights for DTS-201 (a doxorubicin prodrug for targeted cancer therapy) to Diatos. In exchange for these rights, Diatos agreed to pay an upfront payment in cash and stock, milestone payments and royalties on future sales ...

Diatos Moves Its Lead Drug Toward Clinical Trials in Europe

17-Dec-2004 - Diatos S.A. announced the positive review and regulatory clearance of its lead drug DTS-201 Investigational Drug application by the Ethics Committee of Toulouse 1 (France). The AFSSAPS (French Health Products Safety Agency) has already been notified and the company will conduct this initial Phase ...

French Diatos Elected Among the 15 Emerging Biotech Companies 2004 for Its Innovative Technologies and International Developmen

29-Jul-2004 - Paris. Diatos S.A., a privately held biopharmaceutical company, announced today that the company has been elected as an awardee of FierceBiotech's annual "The Fierce 15," a list of the top emerging biotech companies of 2004. Diatos is developing a clinical pipeline of anti-cancer ...

Diatos S.A. Opens Its R&D Subsidiary Diatos N.V. in Belgium

Biotech Fund Flanders (BFF) Makes Initial Investment in Diatos

18-Mar-2004 - Paris and Leuven. Diatos S.A., a privately held biopharmaceutical company, announced the expansion of its operations with the opening of a new research and development center in Leuven, Belgium. Last February the company announced a 7 million Euro round of financing, 3 million Euro of which came ...